Arbutus Biopharma (ABUS) Misses Q3 EPS by 10c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.49), $0.10 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge